Liver transplant study tests Lower-Dose immune drugs to prevent deadly Graft-Versus-Host disease
NCT ID NCT05238155
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 100 liver transplant patients to see if using less immune-suppressing medication could lower the risk of graft-versus-host disease (GVHD), a serious condition where donor cells attack the recipient's body. Researchers tracked how many patients developed GVHD or experienced organ rejection within one year after transplant. The goal was to find a safer balance between preventing rejection and avoiding GVHD.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT VS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Methodist Dallas Medical Center
Dallas, Texas, 75203, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a safer dose of an old drug shield vulnerable children from deadly fungal infections?
- Gene analysis may unlock secrets of bone marrow transplant complication
- Aggressive chemo plus stem cell transplant tested for breast cancer
- Herbal extract shows promise for stiff skin and joints in transplant survivors
- Immune-Guided drug timing could cut CMV prevention after transplant
- New drug shows promise in preventing Graft-Versus-Host disease